Artwork
iconShare
 
Manage episode 513618272 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocking new possibilities for complex format development, and shares a glimpse into Apoha’s future-including an exclusive preview of what’s coming at PEGS Europe this November.

  continue reading

Chapters

1. Opening & Guest Introduction (00:00:00)

2. Data Deluge in Biology (00:01:05)

3. Academic Roots to Startup Leap (00:02:45)

4. Mechanical Waves as Biological Signals (00:04:05)

5. From Membranes to Antibody Delivery (00:06:20)

6. The Liquid Brain Concept (00:08:20)

7. System Architecture & Automation (00:11:05)

8. Why Developability First (00:13:20)

9. Differentiation vs Traditional Assays (00:15:30)

10. Complex Formats: BsAbs and ADCs (00:18:10)

11. State Diagrams as a Third Pillar (00:21:05)

12. Properties as Features of Behavior (00:24:10)

13. Collaboration Models & Access (00:26:00)

14. Roadmap: Explainability, Ecosystem, Deployment (00:29:00)

15. Upcoming Benchmarks & Conference Plans (00:31:20)

16. Closing Thoughts & Listener CTA (00:33:00)

81 episodes